Artimplant 9-month report 2003

STOCKHOLM, Sweden, Nov. 07, 2003 (PRIMEZONE) -- Artimplant:


 ARTIMPLANT DIVESTS GOTHENBURG MEDICAL CENTER
 --    Consolidated net sales January-September 2003 reached SEK 20,3
       million (SEK 18,2 million)
 --    The loss after taxes was SEK 17,4 million (SEK 40,0 million loss)
 --    Earnings per share for the period was SEK -- 0,73 (SEK -4,32)
 --    Gothenburg Medical Center's operations were divested. The cash
       consideration amounts to SEK 11 million.
 --    In August Artimplant received CE-certificate for Artelon Spacer CMC-
       I



 Developments after the 9-month period
 --   Artimplant's board proposes a share issue to raise SEK 48 million.
 Institutional shareholders have announced their intention to subscribe
 to close to 70% of the new shares. A separate press release containing
 additional information has been issued.



 Forthcoming financial reports:
 Release of year end results:       February 17, 2004
 January - March 2004 report:       April 27, 2004
 January - June 2004 report:        August 27, 2004
 January - September 2004 report:   November 5, 2004

Financial reports are available at www.artimplant.se at the same time that they're distributed to the media.

For more information, contact:

ARTIMPLANT

Artimplant is a biomaterial company that focuses on orthopedic surgery solutions. The company runs R&D operations for biodegradable implants and develops manufacturing processes for the implants. Its goal is to enable active lives. Artimplant's biomaterial is based on a new technology that's opening new markets within orthopedic surgery and closely related areas that have extensive med-tech needs. Artimplant developed and patented several different degradable ligament implants that are now in clinical trials. The company's business concept is to license products and technologies to global partners.

Artimplant 9-month report 2003

Mot-clé

Coordonnées

Contact